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quedó limitado al caso del CASMU, y el fondo de garantía previsto con recursos del 
FONASA, se sustituyó con un fondo de rentas generales, que supone un incremento 
potencial del gasto del Estado LECCIONES APRENDIDAS: Aunque no resulta nove-
doso, en primer lugar la experiencia pone de relieve de qué manera las decisiones 
políticas no siempre se alinean con el mejor diseño técnico para la solución del prob-
lema. Por otra parte, este caso en particular puso de maniﬁesto debilidades históricas 
del sistema, que la reforma aún no ha podido modiﬁcar, relacionadas con la calidad 
de las decisiones del regulador, y con su diseño institucional.
PODIUM SESSION I: COST STUDIES I
CS1
COST-EFFECTIVENESS ANALYSIS OF A CERVICAL CANCER VACCINE 
IN FIVE LATIN AMERICAN COUNTRIES
Colantonio L1, Gomez J2, Demarteau N3, Standaert BA4, Pichon-Riviere A1, Augustovski 
FA1, Tatti SA5, Lorenzato F6, Carvalho NS7, Suarez E8, Shigematsu LMR9, Salmeron J10, 
Bautista Garcia F11, Santos Ortiz C11
1Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina, 2GlaxoSmithKline 
Biologicals, Buenos Aires, Argentina, 3GlaxoSmithKline Biologicals, Wavre, Belgium, 
4GlaxoSmithKline Biologicals, Rixensart, Belgium, 5Hospital de Clínicas, University of Buenos 
Aires, Buenos Aires, Argentina, 6GlaxoSmithKline Biologicals, Rio de Janeiro, Brazil, 7Hospital 
de Clinicas, Universidade Federal do Paraná, Curitiba, Brazil, 8University of Chile, Santiago, 
Chile, 9National Institute of Public Health, Cuernavaca, Mexico, 10Instituto Mexicano de 
Seguro Social, Mexico DF, Mexico, 11National Institute of Neoplasic Diseases, Lima, Peru
OBJECTIVES: To assess the cost-effectiveness and cost-utility of adjuvanted HPV-
16/18 vaccination at 12-years of age on top of the current cervical cancer (CC) 
screening program in ﬁve Latin American countries (Argentina, Brazil, Chile, Mexico, 
and Peru). METHODS: A one-year cycle Markov cohort model with a lifetime horizon 
from the health care payer perspective is calibrated with local epidemiology data. The 
model estimates the changes in pre-malignant lesions, CC cases, deaths, life years and 
QALYs saved due to vaccination of a single age-cohort. Efﬁcacy parameter values for 
the base-case with sensitivity analysis are: vaccine efﬁcacy for types HPV-16/18: 95% 
(95%CI: 87.4–98.7%); cross-protection against HPV-31 and HPV-45: 60% (95%CI: 
20.5–80.7%) and 78% (95%CI: 39.3–93.4%) respectively. We discounted both long-
term costs and beneﬁts at 3%, and report in 2007 USD($). One-way sensitivity analy-
sis is performed for achievable screening coverage, HPV-16/18 prevalence in cervical 
cancer, vaccine efﬁcacy, age of vaccination (12–18 years), vaccine cross-protection or 
waning. RESULTS: HPV-16/18 vaccination is predicted to produce a considerable 
reduction on CIN II and III lesions [range: 62.8% (Brazil)—73.5%(Argentina)], CC 
cases [range: 62.7%(Brazil)—73.6%(Argentina)] and CC deaths [range per 100,000 
vaccinated women: 235(Chile)—761(Peru)]. Life expectancy per vaccinated woman 
increases from 17 days (Chile) to 62 days (Peru) (undiscounted values). The ICER per 
QALY saved is $5,964 in Argentina, $10,181 in Brazil, $17,666 in Chile, $10,134 in 
Mexico and $4,576 in Peru. All countries presented an ICER that is below the 3 GDP 
per capita thresholds. Results are most sensitive to the discount rate in all countries, 
and robust to all other parameters. CONCLUSIONS: Universal mass vaccination 
against HPV-16/18 is cost-effective in the current health care setting of each country, 
with a signiﬁcant impact on the wellbeing of the population with a substantial number 
of cervical cancer cases and deaths avoided.
CS2
COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS IN 
SEVEN LATIN AMERICAN COUNTRIES
Pichon-Riviere A1, Augustovski FA2, Bardach A3, Colantonio L3, Rubinstein A2
1Instituto de Efectividad Clínica y Sanitaria (IECS), Ciudad Autónoma de Buenos Aires, 
Argentina, 2Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina, 
3Instituto de Efectividad Clínica y Sanitaria (IECS), Ciudad de Buenos Aires, Buenos Aires, 
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OBJECTIVES: To evaluate the cost-effectiveness of smoking cessation interventions 
(SCI) in seven Latin American countries. METHODS: The health economic model 
structure was deﬁned after analyzing regional decision maker’s information needs and 
the availability and quality of the required epidemiological data in the participating 
countries: Argentina, Bolivia, Brazil, Chile, Colombia, Mexico and Peru. A common 
methodology to retrieve local relevant information was convened and a ﬁrst order 
Monte Carlo, or probabilistic microsimulation of individual patients was built, incor-
porating the natural history, costs and quality of life impact of all the tobacco-related 
diseases: coronary and non-coronary heart diseases, cerebrovascular disease, COPD, 
pneumonia/inﬂuenza, lung cancer as well as 9 other neoplasms. The public health 
perspective and standard discount rate were used. Interventions ranged from brief 
behavioural counselling to intensive pharmacological and cognitive behavioural 
therapy. RESULTS: An initial validation against the Argentinean population showed 
adequate internal validity, with all simulated events rates falling within o 10% of the 
source publications. R2 between predicted and observed values ranged from 0.758 to 
0.999. Third order validation showed an excellent correlation between published data 
and model results. Incremental Cost per QALY were calculated for different sets of 
interventions and target populations in each of the participant countries. Results in 
the cost effectiveness plane and acceptability curves were plotted. Cost per QALY 
showed great variability among treatments and countries. CONCLUSIONS: The 
results of the HEM will allow decision makers in the participating countries to tailor 
coverage policies for tobacco cessation interventions based on the cost-effectiveness 
evaluated for each setting.
CS3
UN MODELO DE COSTO-UTILIDAD DEL TRASPLANTE RENAL EN 
COLOMBIA
Rosselli D
Independiente, Bogotá, DC, Colombia
OBJECTIVOS: El incremento progresivo de la prevalencia de enfermedad renal ter-
minal obliga a los tomadores de decisiones a buscar información de costo-utilidad de 
diálisis y trasplante. Este modelo de Markov simula el curso de vida de pacientes 
sometidos a hemodiálisis (HD) o a trasplante renal con cuatro posibles esquemas de 
inmunosupresión. METODOLOGÍAS: Se utilizaron las tablas de supervivencia de HD 
en Colombia y la información de la red internacional de trasplantes, que trae datos 
de complicaciones (incluyendo rechazo agudo y nefropatía crónica) para los esquemas 
de tacrolimus (TAC) (con mofetil micofenolato MMF o con azatioprina AZA) y de 
ciclosporina (CSA) (con MMF o AZA). La calidad de vida en QALY se obtuvo del 
registro de utilidades de la universidad de Tufts, y los costos fueron de facturación de 
grupos de trasplante de Colombia y de pagadores locales. La perspectiva empleada 
fue la de un tercero pagador, el horizonte temporal toda la vida del paciente, y la tasa 
de descuento 3% anual. Tasa de cambio: US$1  Col$2391. RESULTADOS: La 
intervención menos costosa (US$108K) es la HD, pero es también la que menos QALY 
proporciona (3.84, US$28.1K/QALY). En orden ascendente de costos, los esquemas 
de inmunosupresión reportan: CSA AZA (US$168K; 10.68 QALY; US$15.8K/QALY); 
CSA MMF (US$195K; 13.87 QALY; US$14.1K/QALY); TAC AZA (US$187K; 13.21 
QALY; US$4.1/QALY); TAC MMF (US$214K; 14.85 QALY; US$4.4K/QALY). Las 
razones incrementales de costo-utilidad para el trasplante fue en promedio de US$8.9K 
por QALY adicional ganado, con respecto a la diálisis. CONCLUSIONES: Si se asume 
que la disponibilidad a pagar del sistema de salud es lo que cuesta la diálisis, cualquier 
esquema de inmunosupresión es más costo-útil que la diálisis. Se propone escoger, en 
este caso, el esquema que maximice la utilidad (TAC MMF).
CS4
THE COST AND HEALTH CONSEQUENCES OF SUBCUTANEOUS 
IMMUNOTHERAPY PLUS BECLOMETHASONE DIPROPIONATE IN 
COLOMBIAN CHILDREN WITH MODERATE AND SEVERE ASTHMA
Hernández L1, Castillo M2, García E3
1United BioSource Corporation, Bogotá, Colombia; Universidad de Los Andes, Bogotá, 
Colombia, 2Universidad de Los Andes, Bogotá, Colombia, 3Fundación Santa Fe de Bogotá, 
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OBJECTIVES: To estimate the cost and clinical implications of using subcutaneous 
immunotherapy (SIT) plus beclomethasone dipropionate (BDP) for the treatment of 
moderate and severe asthma due to house dust mites in Colombian children versus 
the conventional therapy with BDP. METHODS: The disease course over 3 years of 
moderate and severe asthmatic children due to house dust mites ages 13 and 14 years 
and treated with BDP with or without SIT was modeled using discrete event simula-
tion; 1000 pairs of identical patients were simulated 100 times. Population character-
istics were obtained from a prevalence study in Colombia. Rates of asthma attacks 
were based on patient’s Peak Expiratory Flow which varies according to patient’s 
treatment. Physician visits, hospitalization and emergency room visit rates were 
extracted from published data. Only direct medical costs were considered; costs are 
reported in 2007 Colombian Pesos (COP) and inﬂated using the Consumer Price Index 
(CPI) where current costs were not available. Costs were discounted at a 3% rate. 
RESULTS: SIT plus BDP decreased the number of asthma attacks in 70% at a cost 
of COP 3,315,959 per patient. Frequencies of physician visits, hospitalizations and 
emergency room visits were predicted to occur less frequently for patients treated with 
SIT plus BDP than with BDP alone. Sensitivity analyses around the time horizon, 6 
and 10 years, showed increasingly better results with SIT plus BDP over time. Sensitiv-
ity analyses around the discount rate for costs were also performed. CONCLUSIONS: 
SIT plus BDP is expected to improve outcomes and save costs compared to BDP alone. 
Thus, it will bring better health to Colombian children suffering from moderate-severe 
asthma at a savings to the Health Authorities.
PODIUM SESSION I: PATIENT-REPORTED OUTCOMES STUDIES
PR1
LITERATURE REVIEW AND PRODUCT LABEL CLAIM REVIEW OF PRO 
MEASURES FOR BENIGN PROSTATIC HYPERPLASIA
Angalakuditi M1, Pokrzywinski R2, Currie B3, Lenderking W3
1Eli Lilly and Company, Indianapolis, IN, USA, 2United BioSource Corporation, Pittsburgh, 
PA, USA, 3United BioSource Corporation, Bethesda, MD, USA
OBJECTIVES: The objective of this research was to review the published literature 
to identify what patient-reported outcome (PRO) measures have been used in evalua-
tion of BPH medications. METHODS: The literature review was carried out in two 
phases: Phase I focused on BPH-speciﬁc treatments and BPH-speciﬁc PRO measures 
while phase II expanded its scope to include other urinary conditions, non-disease-
speciﬁc quality of life PRO measures and utility studies. Phase I included terms for 
BPH and terms for PRO measures. The 279 abstracts were narrowed by focusing on 
medical interventions and more widely read journals. The remaining 125 abstracts 
were reviewed. In Phase II, we expanded the search to include general quality of life 
(QOL) domains in the context of other urinary conditions and utility studies. The 273 
abstracts identiﬁed were reviewed by 2 researchers to isolate the articles of interest, 
leaving 70 articles. RESULTS: We identiﬁed 64 articles from Phase I and 70 articles 
from Phase II. Among the Phase I articles, 52 reported using the International Prostate 
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Symptoms Score (IPSS). 44 articles which used the IPSS were able to detect a signiﬁcant 
change in the symptom scores. The remaining articles used various other PRO mea-
sures for their BPH endpoints. Of the 70 articles yielded from the Phase II search, 11 
were utility studies, 25 were BPH-speciﬁc articles, 29 were overactive bladder (OAB)-
speciﬁc articles, and 5 were urge urinary incontinence (UUI)-speciﬁc articles. From the 
BPH, OAB, and UUI articles, we identiﬁed the key QOL instruments utilized to 
measure the various domains key to BPH. CONCLUSIONS: There have been a large 
number of PRO measures used in the literature to study BPH and related endpoints. 
It is clear that the IPSS has been used in the majority of the studies focused on BPH 
symptoms (81.25% of the ones reviewed).
PR2
IMPROVEMENT IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY 
FOR PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED 
WITH ADALIMUMAB PLUS METHOTREXATE: WORK OUTCOMES AND 
THEIR CORRELATIONS WITH CLINICAL AND RADIOGRAPHIC 
MEASURES FROM A RANDOMIZED CONTROLLED TRIAL COMPANION 
STUDY
van Vollenhoven R1, Cifaldi M2, Ray S2, Chen N2, Weisman MH3
1Karolinska Institutet, Stockholm, Sweden, 2Abbott Laboratories, Abbott Park, IL, USA, 
3Cedars Sinai Medical Center, Los Angeles, CA, USA
OBJECTIVES: To evaluate work productivity of paid workers and homemakers with 
rheumatoid arthritis (RA) treated with adalimumab plus methotrexate (ADAMTX), 
ADA monotherapy, or MTX monotherapy, and to determine baseline predictors of 
work outcomes. METHODS: Data were from the DE032 companion study to 
PREMIER, a 2-year, randomized controlled trial of MTX-naïve patients with early 
RA (3 years). Absenteeism (number of missed work days), presenteeism (patients’ 
self-judgment of effects of RA on work performance), and employment status data 
were collected from self-reports at baseline and varying timepoints during the 2-year 
study. For analyses of cumulative variables, adjustments were made for duration of 
patients’ participation in DE032. RESULTS: Of 799 patients in PREMIER, 664 par-
ticipated in DE032 (ADAMTX, n  219; ADA monotherapy, n  231; MTX mono-
therapy, n  214). Percentages of paid workers and homemakers were similar across 
treatment groups. Among paid workers, the number of missed work days at Year 2 
was signiﬁcantly fewer for ADAMTX (17.4 days) and ADA monotherapy (18.7 days) 
vs. MTX monotherapy (36.9 days, p  0.0001). Improvement in presenteeism was 
greater with ADAMTX vs. MTX monotherapy (p  0.05 at most visits). The percent-
age of patients who retained or gained employment over the 2-year study was 57.6% 
(121 of 210) for ADAMTX, 51.8% (116 of 224) for ADA monotherapy, and 47.6% 
(100 of 210) for MTX monotherapy. The odds of retaining/gaining employment were 
signiﬁcantly greater for ADAMTX vs. MTX monotherapy (odds ratio [OR]  1.53, 
95% conﬁdence interval [CI]: 1.04–2.26, p  0.032). Retaining/gaining employment 
was signiﬁcantly associated with younger age, female sex, and better baseline scores 
on the Health Assessment Questionnaire, Short Form 36 Health Survey, and radio-
graphic progression (joint space narrowing, joint erosion, total Sharp score). 
 CONCLUSIONS: ADAMTX was associated with more positive work outcomes vs. 
MTX monotherapy. Productivity outcomes were similar for paid workers and home-
makers. Radiographic progression at baseline was predictive of employment status.
PR3
EFFECT OF PREHOSPITALIZATION PERIOD AND TYPE OF PESTICIDES 
ON OUTCOMES IN ACUTE ORGANOPHOSPHORUS POISONING
Rose Xavier V1, Thunga G2, Sam KGS2, Kehra K3
1Manipal University, Udupi, karnataka, India, 2Manipal University, Udupi, Karnataka, India, 
3Manipal Acuova, Udupi, karnataka, India
OBJECTIVES: To study the effect of prehospitalization period and type of pesticides 
on outcomes in acute organophosphorus poisoning METHODS: A prospective study 
was conducted with organophosphate poisoning patients admitted to our emergency 
department between January 2007 and January 2008. Information regarding the age, 
sex, occupation, prehospitalization period, type of agent, route of poisoning, clinical, 
laboratory ﬁndings, type of management and subsequent outcome were recorded from 
the patient medical records. The outcomes were analyzed in terms of percentage of 
intermediate syndrome, requirement of ventilation, duration of hospitalization period, 
percentage of mortality, percentage of sequel and percentage of recovery. The out-
comes were compared with preospitalization period and type of pesticides. RESULTS: 
During the study period, 100 patients were admitted to the emergency ward with acute 
organophosphorus poisoning. The estimated mean prehospitalization period after the 
exposure was 2.5 o 2.1 hours. There were 68 male and 32 female patients. The most 
affected age group was 21–30 years (60%). Oral ingestion (99%) was found to be 
the most common route of poisoning. The most frequent reason for poisoning was 
attempted suicide (98%). The most common organophosphate compounds exposed 
were type Ia which was extremely hazardous (60%) and type II which was moderately 
hazardous (25%).Comparing the outcomes with the mean prehosptalization period 
showed that it did not signiﬁcantly affect outcomes in acute OP poisoning, but the 
incidence of intermediate syndrome was higher in these patients. There was signiﬁcant 
correlation between type of compound and outcome. The incidence of intimidate 
syndrome, requirement for ventilation and rate of mortality was signiﬁcantly higher 
in type Ia compounds when compared to other type of pesticides. CONCLUSIONS: 
The prehospitalization period had no inﬂuence on outcomes in acute OP poisoning, 
where as type of OP compounds signiﬁcantly effect incidence of intimidate syndrome, 
requirement for ventilation and rate of mortality.
PR4
QUALITY OF LIFE IN PATIENTS WITH EPIDERMOLYSIS BULLOSA
Tabolli S, Uras C, Paradisi A, Sampogna F, Di Pietro C, Abeni D, Zambruno G
IDI IRCCS, Rome, Italy
Epidermolysis bullosa (EB) is a rare, inherited group of disorders characterized by 
blistering of the skin following friction or mechanical trauma. EB has a clinical and 
socio-economic impact on patients and their families. OBJECTIVES: To assess the 
Quality of Life (QoL) in patients with EB and to determine disease burden. METHODS: 
The study was an observational, cross-sectional postal survey. 185 patients were 
invited to participate. Different sets of questionnaires (SF-36, Skindex-29, GHQ-12, 
EQ-5D) were sent to patients according to age. The perceived severity of the disease 
was evaluated by patients or by the mothers of the younger EB children, using the 
Patient Global Assessment 5-point scale. Caregivers received the Family Strain Ques-
tionnaire (FSQ). RESULTS: A total of 125 respondents were analysed. EB patients 
showed lower values in physical components of SF-36, while the mental ones were 
not signiﬁcantly impaired. Among EB types, junctional EB and severe generalized 
recessive dystrophic EB patients reported lower values and their General Health scale 
was signiﬁcantly different from EB simplex. There were no signiﬁcant differences 
among EB types/subtypes for Skindex-29 values. Females had a worse QoL compared 
to males in each Skindex-29 and SF-36 scales (p  0.05). GHQpositive cases were 
48% among females, 16% among males (p  0.003); GHQpositive cases had a worse 
QoL compared to GHQnegative. The patient QoL and the family burden increased 
with increasing patient’s perceived disease severity and with increasing patient’s body 
surface involved. No differences were seen among EB types for the family burden. 
CONCLUSIONS: In EB patients mental components of SF-36 scores are similar to 
the normal population. The perceived disease severity and skin area involved are rel-
evant for QoL independently by EB type/subtype. EB imposes a heavy burden on the 
caregiver and the family. Psychological support and close monitoring of QoL may 
help EB patients and their caregivers.
PODIUM SESSION I: RESEARCH ON METHODS: I
MC1
VALORACIÓN SOCIAL DE LOS ESTADOS DE SALUD EQ-5D EN CHILE: 
ALCANCES METODOLÓGICOS
Valenzuela P1, Vignau A1, Olivares-Tirado P2, Muñoz A2, Kind P3, Zarate V3
1Consultor DATAVOZ / STATCOM, Santiago, Chile, 2Superintendencia de Salud, Santiago, 
Chile, 3University of York, York, UK
OBJECTIVOS: Obtener la valoración social de los estados de salud de EQ-5D en una 
muestra representativa de la población de Chile y determinar con ello, el índice social 
EQ-5D de la totalidad de estados de salud de EQ-5D (243). METODOLOGÍAS: Se 
entrevistaron a 2000 personas de 20 años y más, residentes de la Región Metropoli-
tana de Chile, a las que se les aplicó el cuestionario EQ-5D/VAS, recogiéndose además 
datos sobre variables sociodemográﬁcas relevantes. Luego, se evaluaron 42 estados de 
salud mediante los métodos VAS, ranking y equivalencia temporal (TTO). Los 42 
estados de salud utilizados corresponden a los mismos utilizados en el estudio Mea-
surement and Valuation of Health (MVH) del Reino Unido en 1993. RESULTADOS: 
Se obtuvo la valoración para los 42 estados de salud, con las diferentes metodologías 
señaladas. Las tasas de respuesta y niveles de consistencia fueron similares a los 
observados en estudios de países desarrollados. Se observó una diﬁcultad decre- 
ciente en la aplicación de las metodologías- VAS, ranking y TTO. Los resultados 
obtenidos mediante las tres técnicas se encuentran muy correlacionados entre si. 
CONCLUSIONES: La colaboración de la población encuestada y el compromiso del 
equipo de encuestadores, al ceñirse estrictamente a la metodología del estudio, res-
paldan la validez y conﬁabilidad de la información recopilada. Un trabajo de campo 
con énfasis en capacitación y control constante del proceso de recopilación de datos, 
permite reducir la tasa de no respuesta a niveles de países desarrollados. La aplicación 
secuencial de las tres metodologías permite obtener muy buenos resultados tanto en 
consistencia interna como en sus correlaciones.
MC2
SELF-PERCEPTION OF HEALTH IN LATIN AMERICA
Cabieses Valdes B1, Espinoza MA2, Zarate V3
1Universidad del Desarrollo, Santiago, RM, Chile, 2Pontiﬁcia Universidad Catolica de Chile, 
Santiago, RM, Chile, 3University of York, York, North Yorkshire, UK
OBJECTIVES: The capacity for planning and implementing public health policies 
requires knowledge and understanding of population’s health status. Information 
traditionally collected in population surveys is related to physical and biological mea-
surements; however, the self-perception of health has recently gained importance. This 
has occurred in light of the widespread phenomenon of an aging population and 
increased prevalence of chronic diseases and disabilities at international level. The 
study compared the self-perception of health-related quality of life (HrQoL) of six 
Latin American countries and its relationship with socio-demographic variables. 
METHODS: This study was based on secondary data collected for World Health 
Survey 2005. Participating countries in the region were Brazil, Paraguay, Uruguay, 
Mexico, Dominican Republic and Ecuador. A probabilistic sample was collected for 
each country, with sex and age national representation (n  67,734). The study 
outcome was HrQoL classiﬁed in 5 categories (Very Good, Good, Moderate, Bad, 
Very Bad). Analyses to estimate the existence of real differences on overall HrQoL 
between countries were performed through binary and ordinal logistic regressions. 
Results were adjusted by sex, age and educational level. RESULTS: The two countries 
